<DOC> 
<DOCNO>1040715_business_story_3497559.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Thursday, July 15, 2004 				 Biocon net surges 112%
 OUR BUREAUX																								July 14: Biocon posted a robust 112 per cent rise in bottomline for the first quarter ended June 30, 2004 due to growth in exports to the US and Europe. Net profit stood at Rs 48.6 crore against Rs 22.9 crore a year-ago. 																								Biocons revenues grew by 65 per cent to Rs 177.9 crore during the first quarter against Rs 107.6 crore last year.																								Our successful entry into the Pravastatin market in Europe following the expiration of product patents in key markets in the region boosted the companys growth. Sales of Lovastatin to the US have also increased subsequent to obtaining the US FDA approval for our submerged fermentation facility. This has enabled us to meet the backlog of orders for Lovastatin, said Biocon CMD Kiran Mazumdar-Shaw.Mastek Q4 profit																								Mastek Ltd has posted a net profit of Rs 6.87 crore for the quarter ended June 30, 2004 compared with Rs 6.73 crore in the same period last year. Total income has increased to Rs 37.96 crore during the quarter under review from Rs 31.54 crore in the previous year. 																								The company posted a lower net profit of Rs 12.74 crore in 2003-04 compared with Rs 38.08 crore in the previous fiscal. Total income decreased to Rs 123.85 crore from Rs 135.81 crore.
</TEXT> 
</DOC>